Global Leukemia Treatment Drugs Market Share
The North American market is anticipated to have a notably large revenue share during the forecast period due to the following factors: a rise in the number of leukemia cases, a growing awareness of personalized medicines, an aging population, the presence of major key players; and significant technological advancements related to leukemia. The US FDA recently approved Jaypirca® (pirtobrutinib) for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor. This approval was granted to companies in North America, including Eli Lilly and Co.
The Asia Pacific market is anticipated to grow at the fastest rate in terms of revenue share and present substantial growth opportunities because of the region's large elderly population, ongoing population growth, economic development, improved healthcare facilities, and increased awareness of leukemia.